Kirill Kosilov1, Sergey Loparev2, Irina Kuzina3, Olga Shakirova4, Natalya Zhuravskaya4, Alexandra Lobodenko3. 1. Department of Social and Psychologikal Science, Far Eastern Federal University, Ayax, 10, F733, Vladivostok, Primorsky Region, Russian Federation. oton2000@mail.ru. 2. Department of Urology, City Polyclinic № 3, Lugivaya 50, Vladivostok, Russian Federation. 3. Department of Social and Psychologikal Science, Far Eastern Federal University, Ayax, 10, F733, Vladivostok, Primorsky Region, Russian Federation. 4. Department of Theory and Methods of Adaptive Physical Education, Far Eastern Federal University, Ayax, 10, S1, Vladivostok, Russian Federation.
Abstract
AIM: Our aim was to determine the efficiency of the Medication Compliance Self-Report Inventory (MASRI) in self-reporting antimuscarinic drug treatment compliance among women with urinary incontinence (UI). MATERIALS AND METHODS: The study assessed 347 women aged 18-65 (averaging 49.7) years with more than one urinary incontinence (UI) episode per day. Treatment compliance was tested at the beginning and at weeks 4, 8, and 12 using the MASRI, the Brief Medication Questionnaire (BMQ), and visual pill counts. The MASRI's constructive, concurrent, and discriminate validity was studied in comparison with an external standard that uses the chi-square and Spearman coefficient. Receiver operating characteristic (ROC) analysis was performed to identify optimum MASRI cutoffs that would predict noncompliance. Furthermore, the functional condition of the lower urinary tract was tested using voiding diaries, uroflowmetry, and cystometry. RESULT: The correlation between the percentage of noncompliant women according to the MASRI, and individuals with a belief barrier with respect to the BMQ screen was r = 0.81 (p ≤0.05), r = 0.84 (p ≤0.05), and r = 0.79 (p ≤0.05). The correlation between the percentage of noncompliant women according to the MASRI and of women who missed >20% of their doses according to the Regimen Screen of the BMQ was r = 0.79, p ≤0.05, r = 0.82, p ≤0.01, r = 0.77, and p ≤0.05 at the control points. Finally, the percentage of noncompliant patients who self-reported correctly according to the MASRI data compared with the BMQ was 95.6%, 95.7%, and 96.6% at the control points. CONCLUSION: The MASRI entails acceptable validity for accurately predicting treatment compliance with antimuscarinic drugs among women who have had UI for >3 months.
AIM: Our aim was to determine the efficiency of the Medication Compliance Self-Report Inventory (MASRI) in self-reporting antimuscarinic drug treatment compliance among women with urinary incontinence (UI). MATERIALS AND METHODS: The study assessed 347 women aged 18-65 (averaging 49.7) years with more than one urinary incontinence (UI) episode per day. Treatment compliance was tested at the beginning and at weeks 4, 8, and 12 using the MASRI, the Brief Medication Questionnaire (BMQ), and visual pill counts. The MASRI's constructive, concurrent, and discriminate validity was studied in comparison with an external standard that uses the chi-square and Spearman coefficient. Receiver operating characteristic (ROC) analysis was performed to identify optimum MASRI cutoffs that would predict noncompliance. Furthermore, the functional condition of the lower urinary tract was tested using voiding diaries, uroflowmetry, and cystometry. RESULT: The correlation between the percentage of noncompliant women according to the MASRI, and individuals with a belief barrier with respect to the BMQ screen was r = 0.81 (p ≤0.05), r = 0.84 (p ≤0.05), and r = 0.79 (p ≤0.05). The correlation between the percentage of noncompliant women according to the MASRI and of women who missed >20% of their doses according to the Regimen Screen of the BMQ was r = 0.79, p ≤0.05, r = 0.82, p ≤0.01, r = 0.77, and p ≤0.05 at the control points. Finally, the percentage of noncompliant patients who self-reported correctly according to the MASRI data compared with the BMQ was 95.6%, 95.7%, and 96.6% at the control points. CONCLUSION: The MASRI entails acceptable validity for accurately predicting treatment compliance with antimuscarinic drugs among women who have had UI for >3 months.
Entities:
Keywords:
Antimuscarinic; Compliance medication; Questionnaire; Self-assessment; Urinary incontinence; Women
Authors: C C Sexton; S M Notte; C Maroulis; R R Dmochowski; L Cardozo; D Subramanian; K S Coyne Journal: Int J Clin Pract Date: 2011-05 Impact factor: 2.503
Authors: Christopher R Chapple; Marcus J Drake; Philip Van Kerrebroeck; Linda Cardozo; Ted Drogendijk; Monique Klaver; Karin Van Charldorp; Zalmai Hakimi; Gerhard Compion Journal: BJU Int Date: 2014-02-20 Impact factor: 5.588
Authors: Tatyana Shamliyan; Jean F Wyman; Rema Ramakrishnan; François Sainfort; Robert L Kane Journal: Ann Intern Med Date: 2012-06-19 Impact factor: 25.391
Authors: Karin S Coyne; Chris C Sexton; Jill A Bell; Christine L Thompson; Roger Dmochowski; Tamara Bavendam; Chieh-I Chen; J Quentin Clemens Journal: Neurourol Urodyn Date: 2012-07-27 Impact factor: 2.696
Authors: Chris C Sexton; Karin S Coyne; Vasudha Vats; Zoe S Kopp; Debra E Irwin; Todd H Wagner Journal: Am J Manag Care Date: 2009-03 Impact factor: 2.229
Authors: Yu Heng Kwan; Livia Jia Yi Oo; Dionne Hui Fang Loh; Truls Østbye; Lian Leng Low; Hayden Barry Bosworth; Julian Thumboo; Jie Kie Phang; Si Dun Weng; Dan V Blalock; Eng Hui Chew; Kai Zhen Yap; Corrinne Yong Koon Tan; Sungwon Yoon; Warren Fong Journal: J Med Internet Res Date: 2020-10-08 Impact factor: 5.428
Authors: Yu Heng Kwan; Si Dun Weng; Dionne Hui Fang Loh; Truls Østbye; Lian Leng Low; Hayden Barry Bosworth; Julian Thumboo; Jie Kie Phang; Livia Jia Yi Oo; Dan V Blalock; Eng Hui Chew; Kai Zhen Yap; Corrinne Yong Koon Tan; Sungwon Yoon; Warren Fong Journal: J Med Internet Res Date: 2020-10-09 Impact factor: 5.428
Authors: Sarah Bentley; Lucy Morgan; Elizabeth Exall; Rob Arbuckle; Rebecca C Rossom; Nicholas Roche; Kamlesh Khunti; Victoria Higgins; James Piercy Journal: Patient Prefer Adherence Date: 2022-09-15 Impact factor: 2.314